Heterologous ChAdOx1-nCoV19-BNT162b2 vaccination provides superior immunogenicity against COVID-19

Lancet Respir Med. 2021 Nov;9(11):1207-1209. doi: 10.1016/S2213-2600(21)00366-0. Epub 2021 Aug 13.
No abstract available

MeSH terms

  • BNT162 Vaccine* / immunology
  • COVID-19* / prevention & control
  • Humans
  • Immunogenicity, Vaccine*
  • Vaccination

Substances

  • BNT162 Vaccine